Heregulin-dependent activation of phosphoinositide 3-kinase and Akt via the ErbB2/ErbB3 co-receptor
about
sameAs
Essential role for Rac in heregulin beta1 mitogenic signaling: a mechanism that involves epidermal growth factor receptor and is independent of ErbB4.Phosphotyrosine interactome of the ErbB-receptor kinase familyIncreased level of phosphorylated akt measured by chemiluminescence-linked immunosorbent assay is a predictor of poor prognosis in primary breast cancer overexpressing ErbB-2.Mechanisms Behind the Resistance to Trastuzumab in HER2-Amplified Breast Cancer and Strategies to Overcome ItWhat a tangled web we weave: emerging resistance mechanisms to inhibition of the phosphoinositide 3-kinase pathwayMemo is homologous to nonheme iron dioxygenases and binds an ErbB2-derived phosphopeptide in its vestigial active siteNeuregulin signaling on glucose transport in muscle cellsErbB4 expression in neural progenitor cells (ST14A) is necessary to mediate neuregulin-1beta1-induced migrationTranscriptional profiling of ErbB signalling in mammary luminal epithelial cells--interplay of ErbB and IGF1 signalling through IGFBP3 regulation.Memo mediates ErbB2-driven cell motility.The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesisHER-3 targeting alters the dimerization pattern of ErbB protein family members in breast carcinomas.Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase.A critical role for HER3 in HER2-amplified and non-amplified breast cancers: function of a kinase-dead RTK.Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors.Bone microenvironment and androgen status modulate subcellular localization of ErbB3 in prostate cancer cellsEndoglin regulates PI3-kinase/Akt trafficking and signaling to alter endothelial capillary stability during angiogenesis.Strong EGFR signaling in cell line models of ERBB2-amplified breast cancer attenuates response towards ERBB2-targeting drugsThe phosphoinositide 3-kinase signalling pathway as a therapeutic target in squamous cell carcinoma of the head and neck.Phosphoinositide 3-kinase signaling is critical for ErbB3-driven breast cancer cell motility and metastasis.Role of HER2/HER3 co-receptor in breast carcinogenesis.GLI pathogenesis-related 1 functions as a tumor-suppressor in lung cancerSystem properties of ErbB receptor signaling for the understanding of cancer progression.HBx sensitizes hepatocellular carcinoma cells to lapatinib by up-regulating ErbB3.Functional impact of sarcopenia in respiratory muscles.Posttranslational protein knockdown coupled to receptor tyrosine kinase activation with phosphoPROTACs.A 45-kDa ErbB3 secreted by prostate cancer cells promotes bone formation.The ERBB3 receptor in cancer and cancer gene therapyNew strategies in HER2-overexpressing breast cancer: many combinations of targeted drugs availableProtein arginine methyltransferase 5 regulates multiple signaling pathways to promote lung cancer cell proliferationFunctional selectivity of EGF family peptide growth factors: implications for cancer.TLR4/MyD88/PI3K interactions regulate TLR4 signaling.The unpluggable in pursuit of the undruggable: tackling the dark matter of the cancer therapeutics universe.A ROR1-HER3-lncRNA signalling axis modulates the Hippo-YAP pathway to regulate bone metastasis.Engineering multivalent antibodies to target heregulin-induced HER3 signaling in breast cancer cellsEffects of ErbB2 Overexpression on the Proteome and ErbB Ligand-specific Phosphosignaling in Mammary Luminal Epithelial Cells.Randomized Phase II Trial of Seribantumab in Combination With Paclitaxel in Patients With Advanced Platinum-Resistant or -Refractory Ovarian Cancer.Overexpression and gene amplification of EGFR, HER2, and HER3 in biliary tract carcinomas, and the possibility for therapy with the HER2-targeting antibody pertuzumab.Heregulin/ErbB3 Signaling Enhances CXCR4-Driven Rac1 Activation and Breast Cancer Cell Motility via Hypoxia-Inducible Factor 1α.hMENA(11a) contributes to HER3-mediated resistance to PI3K inhibitors in HER2-overexpressing breast cancer cells.
P2860
Q24537669-E5ACFC3E-13CD-444C-9DF5-DBA5801E54E2Q24672516-EB3AA68A-00F9-486F-AA89-F891EE6DF45EQ24810517-D6E4C50C-A97F-40DF-B826-E90563F29479Q26752780-2EECC064-1EBD-42C5-8E2E-B8F857708B53Q26825780-A54095B1-0B29-4B64-8245-55F1B8F15414Q27649163-2DA9BF97-CC44-41E0-9BDF-0EEE3893166DQ28571833-7E5D404B-9F56-40B4-921B-BBCE5B160F5FQ28578116-4078742A-D1E5-4284-AC61-DF2C6FB8C810Q33692428-4009825A-8E2B-45A0-9B2D-FEF4976036F9Q34322240-5384D8E6-3BFF-4F21-B7F8-8A512F1843C0Q34493341-8C68F076-CFCE-4D82-93BD-369BECFB810EQ34506951-C33B90C8-9A9D-4AA5-A327-6B0FA5BF4456Q34720797-4D54B49D-872A-41F2-8F5C-77AD32684FC5Q35682599-3556192E-1207-4E53-BFBE-5EEA8E3841E1Q35779022-A2F2BC6D-4D81-4783-BA60-666B9A1567E3Q36025400-2F9D527C-7F93-4159-B88D-4208050D03C6Q36066614-F94F3D74-C86B-4B98-A265-B4AB2FB2DCDDQ36143159-CC0D8FF2-B282-4887-AD38-4659C1408E77Q36219713-A6BED525-417D-4832-991C-B30DA242D724Q36311874-06EE9E63-6937-4BC3-9766-44F4FC97D4E6Q36429652-E76462F8-6222-40D2-AB4B-76EE228A7833Q36701254-0DC3A61D-3C83-4E3B-95F4-3E83F77FA732Q36716462-A2551FD3-613A-4BC0-9473-031238FC4252Q36729450-F1C5A144-07E3-4D31-BA54-4FB64BDDAC32Q36818574-B97614D2-CF3E-487E-889B-C3EE0D6A164DQ36895558-1C73EB48-B2B7-43BC-854D-44B42725C203Q36925694-1BAA6FD3-4949-4DB6-8D7E-5756EF2F90F2Q37135372-D5BB2B11-383F-44ED-A738-798297F24B7CQ37144315-87314999-2A1A-484B-86D0-81D76ECD4FC0Q37145814-731D46A1-0C0D-4EBA-B9EB-4FC1C90F0868Q37149729-A0B46538-3F88-4942-9D1D-A5683C80424CQ37232951-6760FB3E-9296-4ED3-BEBC-79985A8E36D6Q37385372-7F50E454-DD1F-43F5-A8E6-5BD087D4529DQ37679659-8ADB30F0-6C2F-4FF5-A5D9-E77B6677ED9CQ37698914-F8A10357-1F0C-40B8-A3C3-66A8D8358B3FQ37740757-E8E724BD-1F36-4777-B844-A8EC7F2D4B3EQ38376696-F0A66AD1-E3B8-4BCB-A6DF-ACA940694441Q38390565-7DEA70AF-1A72-40AA-9564-921F47CE1890Q38770505-3E841016-5C8E-4203-8A2B-C20937BE05E1Q38876630-785A767C-C975-4C25-889D-B760918E7D4C
P2860
Heregulin-dependent activation of phosphoinositide 3-kinase and Akt via the ErbB2/ErbB3 co-receptor
description
2001 nî lūn-bûn
@nan
2001 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Heregulin-dependent activation ...... ia the ErbB2/ErbB3 co-receptor
@ast
Heregulin-dependent activation ...... ia the ErbB2/ErbB3 co-receptor
@en
Heregulin-dependent activation ...... ia the ErbB2/ErbB3 co-receptor
@nl
type
label
Heregulin-dependent activation ...... ia the ErbB2/ErbB3 co-receptor
@ast
Heregulin-dependent activation ...... ia the ErbB2/ErbB3 co-receptor
@en
Heregulin-dependent activation ...... ia the ErbB2/ErbB3 co-receptor
@nl
prefLabel
Heregulin-dependent activation ...... ia the ErbB2/ErbB3 co-receptor
@ast
Heregulin-dependent activation ...... ia the ErbB2/ErbB3 co-receptor
@en
Heregulin-dependent activation ...... ia the ErbB2/ErbB3 co-receptor
@nl
P2860
P3181
P356
P1476
Heregulin-dependent activation ...... ia the ErbB2/ErbB3 co-receptor
@en
P2093
P2860
P304
42153-42161
P3181
P356
10.1074/JBC.M102079200
P407
P577
2001-09-06T00:00:00Z